ExAdEx-Innov develops an innovative and upscalable biotherapy for the treatment of obesity-associated chronic metabolic diseases in total therapeutic failure, such as NASH, as well as Type-2 diabetes and complex obesity forms not responding to treatments. The patented ExAdEx core technology also allows to derisk drug development through a unique R&D ex vivo platform of human adipose tissue mimicking pathological contexts to generate clinically-relevant data at preclinical stage.